To include your compound in the COVID-19 Resource Center, submit it here.

Telcyta: Phase II data; Phase III

Interim results from an ongoing U.S. Phase II trial of Telcyta as monotherapy in

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE